BRAF and ameloblastoma: In the study of Marcelino et al. (8), the authors identified 81.2% as positive and 18.8% as negative ameloblastomas for the anti-BRAF V600E antibody by immunohistochemistry; and, for PCR analysis, it was showed 82.8% cases of ameloblastomas as positive and 17.2% as negative for the BRAF V600E mutation.